Hikal Acquired Pharmaceutical Fine Chemicals from Wintac

Alperowicz, Natasha
March 2001
Chemical Week;3/14/2001, Vol. 163 Issue 11, p20
Trade Publication
Reports on the acquisition by fine chemicals producer Hikal of the research and development and active pharmaceuticals manufacturing unit of Wintac. Aim of the acquisition; Information on an exclusive synthesis agreement of Hikal with Merck & Co.; Sales of Hikal in the fiscal year ended March 31, 2000.


Related Articles

  • Merck CEO Clark: Marketing, sales positions could be cut. M. I. // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p14 

    The article reports on the plan to lay off employees of Merck & Co. Inc. in the wake of its merger with Schering-Plough Corp.

  • Trust us on Medco: Merck to NARD members.  // Drug Topics;11/8/93, Vol. 137 Issue 21, p5 

    Presents the side of Merck & Co. on the merger with Medco. Speech to the National Association of Retail Druggists' (NARD ) annual meeting by executives; Interest in Medco's information systems capability as prime reason for purchase.

  • Merck-Medco to become stand-alone PBM. Ukens, Carol // Drug Topics;2/18/2002, Vol. 146 Issue 4, p12 

    Reports on the separation plans of Merck & Co. Inc. from a merger with Medco Containment Services. Objective of the separation plans; Optimism shown by the National Community Pharmacists Association regarding the separation plans; Advantage of the deal for Merck and the pharmacy benefit...

  • Pharma consolidation continues.  // TCE: The Chemical Engineer;Apr2010, Issue 826, p6 

    The article reports on the merger and consolidation of pharmaceutical companies Sonofi-Aventis and Merck, and the acquisition of German generic drug company Ratiopharm by Israeli generic drug manufacturer Teva.

  • Merck Buys cCAM Biotherapeutics in $605M Deal.  // Contract Pharma;Sep2015, Vol. 17 Issue 7, p148 

    The article reports on the acquisition by pharmaceutical company Merck & Co. Inc. of the biopharmaceutical company CCAM Biotherapeutics which focuses on the development and discovery of cancer immunotherapies.

  • IS THIS THE BIG DRUG DEAL?  // Business News New Jersey;05/15/2001, Vol. 14 Issue 20, p3 

    Reports on the offer made by Merck to buy Schering-Plough through a stock deal. Previous stand of the two companies on the consolidation activities in United States the pharmaceutical industry; Problems experienced by Schering-Plough with the Food and Drug Administration.

  • Merck lands biopharma in $9.5B deal. Strauss, Eric // njbiz;12/15/2014, Vol. 27 Issue 50, p2 

    The article reports that drugmaker Merck is in the process of acquiring biopharmaceutical firm Cubist Pharmaceuticals Inc., and mentions topics that include details relating to the acquisition transaction, Cubist's portfolio, and the advantages of merging Merck and Cubist.

  • CORPORATE.  // MondayMorning;12/21/2009, Vol. 17 Issue 49, p2 

    The article offers news briefs related to the mergers and acquisition of corporates related to the healthcare industry. The largest health-products company of the world, Johnson & Johnson plans to buy Acclarent Inc. for 785 million dollars. Merck Sharp & Dohme Ltd., a subsidiary of Merck & Co....

  • The New Merck's Move on Emerging Markets. Looney, William // Pharmaceutical Executive;Mar2010, Vol. 30 Issue 3, p36 

    The article focuses on the business strategies of Merck & Co. Inc. in the pharmaceutical industry in emerging markets. The role of Stefan Oschmann as president of Merck's European operations is seen as a pivotal one for the company's long-term organic growth. The company has merged with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics